Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (51)	6/6/2001 11:21:57 PM
From: The Dodgy Ticker	Respond to of 897

<<Glad to hear you're doing well!>> I'm doing well because it's not hard to follow your footsteps (and Peter's and a few of the other SI biofreaks)! I second the comments of someone else recently who said what priceless information these SI biotech threads make available to those of us without the background. Even Michael Young will come to appreciate this if he hangs around long enough. I owe ya, and thanks! Bob

To: scaram(o)uche who wrote (51)	6/7/2001 1:41:26 AM
From: Doc Bones	Read Replies (1) \| Respond to of 897

Rick, Your "stock picking" skills worked fine in the "old biology," but its now imperative to shift paradigms. Allow me to explain some of the fundamentals of the "new biology," if I may. All stocks that announce a secondary today will go down 2 points, 4 points for a "flagrant" secondary. Other stocks may go up 2 points, with points added as always for those who can pump out a plausible press release. In addition, PDLI gets +- 5 bonus points, depending on how the Naz goes. Clear enough, I hope? Doc